Navigation Links
Barta joins Conseco as Senior Vice President, Financial Planning & Analysis; Barra named Senior Vice President, Internal Audit; Clarke to head Investor Relations
Date:10/11/2007

CARMEL, Ind., Oct. 11 /PRNewswire-FirstCall/ -- Conseco, Inc. (NYSE: CNO) announced the appointment of three senior financial officers, effective Oct. 15, 2007:

-- Thomas D. Barta will join Conseco as Senior Vice President -- Financial

Planning & Analysis, reporting to Conseco CFO Ed Bonach.

-- David J. Barra will become Senior Vice President -- Internal Audit,

with responsibility for audit and enterprise risk assessment. In his

new role, Barra will report to Neal Schneider, chair of the Audit

Committee of the Board of Directors, and to Conseco CEO Jim Prieur.

-- Joseph P. Clarke, Vice President -- Financial Planning & Analysis, will

take on additional responsibility for Conseco's investor relations and

relationships with rating agencies. He will report to Mr. Barta.

"We are pleased to add Tom to our leadership team, and we are fortunate to have Dave and Joe assume these important new roles," Bonach said. "Tom brings over 25 years of diversified financial management, leadership and international experience. Dave's extensive company, business and audit experience will significantly enhance our effort to improve Conseco's enterprise risk profile. Joe's knowledge of the company and leadership role in financial planning and analysis will benefit investor relations and our interactions with rating agencies."

Mr. Barta joins Conseco from Allianz Life Insurance Company of North America, where he was Vice President and Senior Finance Director -- Distribution. During his 20 years with Allianz, he also served expatriate assignments with the company's Americas Division Life Operations and the Group Finance Department in Munich, Germany, and served the North American company in controller, treasury and audit management roles. A Certified Public Accountant, Chartered Life Underwriter, and Fellow of the Life Management Institute, Mr. Barta earned a BSB degree in Accounting and an MBA in
'/>"/>

SOURCE Conseco, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Ranbaxy joins hand with Cipla to co-market ciprofloxacin
2. Rat joins list of cloned animals
3. Richard Gere Joins Indian Stars For Fight Against AIDS
4. Enbrel Joins with Methotrexate to Cure Rheumatoid Arthritis
5. Anoushka Joins Hands With WFP to Feed the Poor
6. India Joins Hands With Global Body for Vaccine Research
7. Another Statewide Organization Joins the Fight Against Assisted Suicide
8. Two-year-old Joins Mensa, Becomes Its Youngest Ever Genius
9. Senior drug card saves little
10. Reducing Depression In Seniors
11. A sharp increased in senior citizens: set to outpace children.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/12/2008)...- Emphasys Medical Inc.,today announced that one-...any,s Zephyr(R) Endobronchial Valve (EBV) will be ...merican Thoracic Society (ATS) occurring,May 16 to...00 a.m. (ET), Metro Toronto Convention Centre,Roo...ma Treatment: Lung Volume,Reduction and Lung Volum...
(Date:5/12/2008)...drugs may help prevent heart attacks during surger...or stroke, says a major study to be published onli...ancet. , POISE is the worlds largest randomized ...ns. POISE evaluated the effects of a beta-blocker...of surgery. , POISE demonstrates that a beta-bl...
(Date:5/12/2008)...rstCall/ -- China Yingxia,International, Inc. (OTC...mpany"), a leading provider in the nutraceutical i...d distribution of organic nutritional food,product...People,s Republic,of China ("PRC"), announced toda...6, 2008, at 10:00 a.m. EDT, to discuss the Company...
(Date:5/12/2008)...bank Farms, a national,ground beef producer, is is...roducts produced at its Ashville, N.Y., facility a...ilson Farms retail outlets and C&S Wholesale,distr...ieces of hard plastic. All,recalled products have ...a,"Julian date 124" on the package,s label. The pr...
Breaking Medicine News(10 mins):Health News:Emphasys Medical to Present VENT Clinical Trial Data at ATS 2008 2Health News:Metoprolol around the time of surgery increases the risk of death and stroke: POISE trial 2Health News:Metoprolol around the time of surgery increases the risk of death and stroke: POISE trial 3Health News:China Yingxia International, Inc. Announces Conference Call to Discuss First Quarter 2008 Results 2Health News:Fairbank Farms Issues Voluntary Recall for Selected Ground Beef Products 2
... be an effective vaccine against recurrent kidney ...ent of all cancers and causes about 12,000 deaths ...often strikes those in their 50s and 60s. Standard... kidney. Unlike some other cancers, however, kidne...
...s some of its effectiveness in the first year afte...te their children against chickenpox between 12 mo... prompted to further investigate the vaccine after...g vaccinated individuals. Researchers studied nea...
Cholesterol-lowering drug Found To greatly Reduce the risk of stroke and heart attack
... the drugs for at least 501 days -- faced double t...rage of about 17 years, compared with women who di...antibiotics are widely used to treat a variety of ...me pneumonias and many gastrointestinal infections...
Other Medicine News:
(Date:5/9/2008)...s Following Bunionectomy,, TAMPA, Fla., May 9 ...nts experience intense pain for several days follo...oot surgeries. The investigational pain,medication...ts who had this,surgery, compared to those treated...lted in patients reporting fewer gastrointestinal ...
(Date:5/9/2008).../ -- Ardea Biosciences, Inc.,(Nasdaq: RDEA ), a c...,small- molecule therapeutics for the treatment of...gout, today announced that John W. Beck,has been a...ions and Chief,Financial Officer effective May 27,...shortly thereafter. The Company also reported rece...
(Date:5/9/2008)...ows Positive Results with X-ray ...wire/ -- Roche today announced one-year,results fr...EMRA(TM),(tocilizumab) can significantly inhibit p...nts with rheumatoid arthritis (RA), a critical mea...y also demonstrated that ACTEMRA,reduces disease s...
(Date:5/8/2008).../ -- DATATRAK International, Inc.,(Nasdaq: DATA )...bal,eClinical solutions for the clinical trials in...he first quarter of 2008., For the three months e...ly 41% to $2,088,000 and the Company reported a ne...th a basic and diluted basis. These,results compar...
Breaking Medicine Technology:New Data From Phase 3 Study Suggests Tapentadol Immediate Release Effective for Acute Pain From Common Foot Surgery 2New Data From Phase 3 Study Suggests Tapentadol Immediate Release Effective for Acute Pain From Common Foot Surgery 3New Data From Phase 3 Study Suggests Tapentadol Immediate Release Effective for Acute Pain From Common Foot Surgery 4New Data From Phase 3 Study Suggests Tapentadol Immediate Release Effective for Acute Pain From Common Foot Surgery 5Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 2Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 3Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 4Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 5Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 6New Study Demonstrates ACTEMRA(R) (tocilizumab) Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients 2New Study Demonstrates ACTEMRA(R) (tocilizumab) Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients 3New Study Demonstrates ACTEMRA(R) (tocilizumab) Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients 4New Study Demonstrates ACTEMRA(R) (tocilizumab) Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients 5DATATRAK International Reports First Quarter Results for 2008 2DATATRAK International Reports First Quarter Results for 2008 3DATATRAK International Reports First Quarter Results for 2008 4DATATRAK International Reports First Quarter Results for 2008 5DATATRAK International Reports First Quarter Results for 2008 6DATATRAK International Reports First Quarter Results for 2008 7New Benefactors Show Support for CDA4CDT 3A 2638 1New Benefactors Show Support for CDA4CDT 3A 2638 2New Benefactors Show Support for CDA4CDT 3A 2638 3New Benefactors Show Support for CDA4CDT 3A 2638 4New Benefactors Show Support for CDA4CDT 3A 2638 5New Benefactors Show Support for CDA4CDT 3A 2638 6New Benefactors Show Support for CDA4CDT 3A 2638 7Angiotech and Symphony Medical Announce Licensing Agreement 2636 1Angiotech and Symphony Medical Announce Licensing Agreement 2636 2Angiotech and Symphony Medical Announce Licensing Agreement 2636 3Angiotech and Symphony Medical Announce Licensing Agreement 2636 4Angiotech and Symphony Medical Announce Licensing Agreement 2636 5Angiotech and Symphony Medical Announce Licensing Agreement 2636 6Newly discovered virus linked to deadly skin cancer 9721 1Newly discovered virus linked to deadly skin cancer 9721 2Newly discovered virus linked to deadly skin cancer 9721 3Newly discovered virus linked to deadly skin cancer 9721 4Scripps research scientists find new genetic mutation that halts the development of lupus 9720 1Scripps research scientists find new genetic mutation that halts the development of lupus 9720 2Scripps research scientists find new genetic mutation that halts the development of lupus 9720 3
...ND OAKS, Calif. & COLLEGEVILLE, Pa.--(BUSINESS...th Pharmaceuticals, a,division of Wyeth (NYSE:WYE)...ata that showed that the safety profile of Enbrel(...in patients with,moderate-to-severe juvenile rheum...ars of therapy. JRA is a chronic autoimmune,diseas...
...inical Studies Show 227Th-rituximab More Effective...tiuxetan-ibritumomab,(Zevalin) , OSLO, Norway, 14 ...n cancer therapeutics company, announces that a re...hnology for targeted,cancer therapy has been publi...ficial journal of the American Society of Hematolo...
Other Medicine Technology:Enbrel Safety Data for up to Eight Years in Patients with Juvenile,Rheumatoid Arthritis Being Presented at EULAR 2Enbrel Safety Data for up to Eight Years in Patients with Juvenile,Rheumatoid Arthritis Being Presented at EULAR 3Enbrel Safety Data for up to Eight Years in Patients with Juvenile,Rheumatoid Arthritis Being Presented at EULAR 4Enbrel Safety Data for up to Eight Years in Patients with Juvenile,Rheumatoid Arthritis Being Presented at EULAR 5Enbrel Safety Data for up to Eight Years in Patients with Juvenile,Rheumatoid Arthritis Being Presented at EULAR 6Enbrel Safety Data for up to Eight Years in Patients with Juvenile,Rheumatoid Arthritis Being Presented at EULAR 7Enbrel Safety Data for up to Eight Years in Patients with Juvenile,Rheumatoid Arthritis Being Presented at EULAR 8Algeta Demonstrates Targeted Cancer-killing Potential of Novel,Alpha Particle Linked Antibodies in Leading Medical Journal Blood 2Algeta Demonstrates Targeted Cancer-killing Potential of Novel,Alpha Particle Linked Antibodies in Leading Medical Journal Blood 3Algeta Demonstrates Targeted Cancer-killing Potential of Novel,Alpha Particle Linked Antibodies in Leading Medical Journal Blood 4
... reference laboratory and a worldwide leader in in... offers an extensive test menu of highly complex a...athology. Owned by the University of Utah, ARUP La...nation's university teaching hospitals and childre...
... reference laboratory and a worldwide leader in in... offers an extensive test menu of highly complex a...athology. Owned by the University of Utah, ARUP La...nation's university teaching hospitals and childre...
... reference laboratory and a worldwide leader in in... offers an extensive test menu of highly complex a...athology. Owned by the University of Utah, ARUP La...nation's university teaching hospitals and childre...
... reference laboratory and a worldwide leader in in... offers an extensive test menu of highly complex a...athology. Owned by the University of Utah, ARUP La...nation's university teaching hospitals and childre...
Medicine Products: